Brain protein may reveal who will regain weight after stopping popular weight loss drugs
NCT ID NCT06795360
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 52 adults who are about to stop taking injectable weight loss drugs due to insurance changes. Researchers will measure a brain protein called Agouti-related peptide (AgRP) and track weight changes over 3 months. The goal is to see if this protein can predict who will regain weight after stopping the medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
discontinuation of weight loss medication
What this could lead to
If successful, this could help identify people at risk of regaining weight after stopping injectable weight loss drugs, allowing for better personalized care.
What could go wrong
This is a small observational study with only 52 participants, so results may not apply to everyone. It only looks at a 3-month period, so longer-term effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••